Shareholders in Amicus Therapeutics (NASDAQ:FOLD) Have Lost 31%, as Stock Drops 4.7% This Past Week

Simply Wall StJan 4 03:17

Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireJan 2 20:00

Jefferies Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $18

Futu NewsDec 17, 2024 21:31 · Ratings

Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus

Seeking AlphaDec 14, 2024 03:42

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

BenzingaDec 14, 2024 03:10

Amicus Therapeutics (FOLD) Is a Top-Ranked Momentum Stock: Should You Buy?

Yahoo FinanceDec 13, 2024 22:50